10-Q: Advanced Biomed Reports Wider Q3 Loss, Going Concern Doubt

Advanced Biomed Inc. reported a significantly wider net loss and increased cash burn from operations for the quarter ended September 30, 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• Advanced Biomed Inc. reported a net loss of $386,901 for the three-month period ended September 30, 2025, a 46% increase from $265,580 in the same period last year.
• Net cash used in operating activities significantly increased to $610,342 for the quarter, compared to $29,680 in the prior year period.
• Research and development expenses rose by 30% to $235,992, driven by increased clinical development activities.
• General and administrative expenses decreased by 15% to $287,922, primarily due to lower staff costs, traveling, entertainment, and miscellaneous expenses.
• Other income, net, decreased by 46% to $136,565, mainly due to a lower foreign exchange gain.
• The company's working capital surplus decreased to $2,799,181 as of September 30, 2025, from $3,143,443 as of June 30, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to recurring net losses and significant cash outflows from operations.
• The company completed its initial public offering on March 7, 2025, raising gross proceeds of $6.56 million.
• An Equity Line of Credit (ELOC) agreement was entered into on June 6, 2025, allowing the company to sell up to $25,000,000 of common stock to HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD.
• The company is developing several oncology detection and diagnosis products, with some cleared by China's NMPA, others in application, and four immunostaining kits under registration review.
• Clinical research for the A+LCGuard Lung Cancer Early Screening Kit is planned to begin in January 2026 and conclude by June 2026, pending ethical review approval by December 2025.
• Expansion plans include establishing operation centers in North America (California and Washington) and Europe in January 2026 for localized product registration, testing, and production.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significantly wider net loss, a substantial increase in cash burn from operations, and an explicit 'going concern' warning. While there are positive developments like the IPO and ELOC agreement, these are overshadowed by the deteriorating financial performance and the high-risk nature of pre-revenue biotech operations with ongoing losses expected for the next 2-3 years.

Positives

• Successful completion of an Initial Public Offering on March 7, 2025, raising gross proceeds of $6.56 million.
• Secured an Equity Line of Credit (ELOC) agreement on June 6, 2025, providing access to up to $25,000,000 in capital.
• Two key products, A+Pre and AC-1000, along with their corresponding microfluidic chips, have received clearance from China's NMPA.
• Previous scientific research project for A+Pre, AC-1000, and A+LCGuard demonstrated high effectiveness with 96% sensitivity and 99.9% specificity.
• General and administrative expenses decreased by 15% for the three-month period ended September 30, 2025, indicating some cost control.
• Cash at the end of the period remained relatively stable at $2,656,519 compared to $2,646,992 in the prior year period.

Negatives

• Net loss for the three-month period ended September 30, 2025, widened by 46% to $386,901 from $265,580 in the prior year.
• Net cash used in operating activities increased significantly to $610,342 for the quarter, compared to $29,680 in the prior year period, indicating a higher cash burn.
• Working capital surplus decreased to $2,799,181 as of September 30, 2025, from $3,143,443 as of June 30, 2025.
• The company has not generated any revenue from product sales since inception and does not expect to until regulatory approvals are obtained.
• Management explicitly states an expectation of continuous losses for the next two to three years.
• Other income, net, decreased by 46% due to lower foreign exchange gains.
• Loss per share increased to $0.02 from $0.01 in the prior year period.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses and significant cash outflows from operating activities.
• The company's ability to continue as a going concern depends on its capacity to develop, register, and obtain regulatory approval for commercial sale of its products to generate positive operating cash flows.
• Reliance on raising additional capital, cash generated from upcoming operations, and financial support from related parties and stockholders to sustain operating activities.
• Clinical research results may differ from expectations and may not support progression to large-scale clinical trials, requiring product optimization or protocol adjustments.
• Delays in obtaining ethical approval or recruiting participants could prevent clinical research from being completed on schedule, postponing large-scale clinical trials and product launch dates.
• Inability to obtain device and product approvals or provide product service on time due to differences in regulatory and clinical registration requirements across various regions/countries.
• The company's business, financial condition, and results of operations may be adversely influenced by political, economic, and legal environments in Taiwan and mainland China.
• Potential negative impact from natural disasters, extreme weather conditions, health epidemics, and other catastrophic incidents.
• Fluctuations in foreign currency exchange rates (NT$, CNY, HKD against US$) may materially affect financial condition.
• Restrictions imposed by PRC and Taiwan laws and regulations on the ability to transfer cash between countries and subsidiaries, or distribute earnings to the parent company or U.S. investors.
• Inflationary pressures, particularly on research and development costs and staff salaries, could affect profitability and operating results.

Future Outlook

The company expects to remain in a state of continuous loss for the next two to three years as it focuses on clinical development and regulatory approvals. It plans to initiate clinical research for its A+LCGuard product in January 2026, with completion anticipated by June 2026, and aims to obtain the required registration certificate by October 2027. The company also intends to expand globally by establishing operation centers in North America and Europe in January 2026 for localized product registration, testing, and production. Management believes existing cash will be sufficient for at least twelve months, but acknowledges the need for additional financing and the uncertainty of its availability.

Management Comments

• "We expect to be in a state of continuous loss for the next two to three years."
• "We plan to begin the clinical research for A+LCGuard in January 2026, and we anticipate the clinical research will end in June 2026."
• "We believe the results of the clinical research will inform the work plan for future large-scale clinical trials, minimizing waste from an excessively large sample size or insufficient statistical power due to a sample size that is too small."
• "We recognize that the clinical research results may differ from expectations and may not support our expected progression to clinical trials. If so, we plan to promptly optimize the product, adjust participant group selection, and modify the final protocol for large-scale clinical trials."
• "We cannot guarantee that any clinical research or trial will meet our anticipated outcomes."
• "Delays in obtaining ethical approval or recruiting participants could prevent the clinical research from being completed on schedule. Such delays could subsequently postpone the large-scale clinical trial and ultimately the product launch date."
• "Management has commenced strategies to raise debts from related parties and stockholders and equity."
• "In the event of unforeseen circumstances that disrupt the above-mentioned financial projection and strategies, the Company believes that our existing cash $2,656,519 as of September 30, 2025 will be sufficient to meet our research and development and operating expenditures for a minimum period of approximately twelve months from the date of this Report."
• "However, there can be no certainty that these additional financings will be available on acceptable terms or at all. If management is unable to execute this plan, there would likely be a material adverse effect on the Companys business."

Industry Context

Advanced Biomed operates in the highly competitive and regulated precision oncology detection and diagnosis industry. Its focus on microfluidic biochip technology for early cancer screening and treatment aligns with a growing trend towards personalized medicine and non-invasive diagnostics. The planned expansion into North America and Europe indicates an ambition to compete on a global scale, but also highlights the significant regulatory hurdles and capital requirements inherent in the biotech sector. The company's current stage of development, characterized by significant R&D expenses and no revenue, is typical for early-stage biotech firms, but the explicit 'going concern' doubt underscores the high-risk nature of this phase.

Comparison to Industry Standards

• The company's reported 96% sensitivity and 99.9% specificity for A+LCGuard in a scientific research project at Shanghai Pulmonary Hospital are strong indicators for a lung cancer early screening kit. For example, liquid biopsy tests for lung cancer from companies like Guardant Health (Guardant360) or Grail (Galleri) aim for high sensitivity and specificity, often in the range of 85-99% depending on cancer stage and type. However, this was a scientific research project, not a formal clinical trial, and thus not directly comparable to FDA/NMPA approved product performance data.
• The company's current financial state, with no revenue and significant net losses, is common for pre-commercial biotech companies. However, the substantial increase in cash used in operating activities ($610,342 in Q3 2025 vs. $29,680 in Q3 2024) and the explicit 'going concern' warning indicate a higher level of financial distress compared to many peers who might have longer cash runways or more diversified funding sources at a similar stage.
• The ELOC agreement for up to $25 million provides a potential funding mechanism, but its utilization depends on market conditions and the company's stock price, which can be volatile for pre-revenue companies. This is a common financing tool for smaller companies but often comes with dilution risks.

Legal Proceedings

• The company is not a party to any litigation, arbitration, or administrative proceedings that are believed to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• Amounts due to major stockholders (Yi Lu, Ph.D., Chen-Yi Lee, Hung To Pau, Ph.D.) totaled $50,013 current and $120,984 non-current as of September 30, 2025. These are non-trade, unsecured, interest-free, and repayable on demand or over one year.
• Amounts due to related corporations (Well Fancy Development Ltd, Shanghai Junfu Electronic Technology Co., Ltd.) totaled $1,435,065 current and $69,975 non-current as of September 30, 2025. These are non-trade, unsecured, interest-free, and repayable on demand or over one year.
• Advanced Biomed Inc. (Taiwan) provided an unsecured, interest-free loan of approximately US$117,472 to Yi Lu, Ph.D. for general working capital in January 2023.
• Shanghai Sglcell Biotech Co., Ltd. provided several unsecured, interest-free loans to Hung To Pau, Ph.D. totaling approximately US$48,497 for general working capital as of September 30, 2025.
• Advanced Biomed Inc. (Taiwan) and Advanced Biomed Inc. (HK) provided multiple unsecured, interest-free loans to Well Fancy Development Ltd totaling approximately US$655,201 for general working capital as of September 30, 2025.
• Shanghai Sglcell Biotech Co., Ltd. provided multiple unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. totaling approximately US$849,839 for general working capital as of September 30, 2025.
• Certain related parties waived $2,820,624 due to them as of June 30, 2024, to improve the company's working capital.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity raises (ELOC agreement) and ongoing losses. The 'going concern' doubt poses a substantial risk to investment value.
• **Employees:** Continued R&D activities and expansion plans suggest ongoing employment opportunities, but the company's financial instability could create uncertainty.
• **Creditors:** Related party creditors have provided interest-free, unsecured loans, indicating a supportive but exposed position. Third-party creditors face risks due to the 'going concern' doubt.
• **Customers (Future):** The development of new oncology products and planned global expansion could eventually benefit patients and healthcare providers, but delays in regulatory approval are a risk.
• **Suppliers:** May face payment risks if the company's liquidity issues worsen, although current liabilities are being managed.

Next Steps

• Obtain ethical review and ethics committee approval for the A+LCGuard clinical research protocol by the end of December 2025.
• Initiate the trial stage of A+LCGuard clinical research in January 2026.
• Complete A+LCGuard clinical research by June 2026.
• Optimize products, adjust participant group selection, and modify large-scale clinical trial protocols if initial clinical research results differ from expectations.
• Complete site selection and personnel recruitment in the United States in January 2026.
• Start product registration, testing, and production in the United States after site selection and recruitment.
• Break into the European market in January 2026 and conduct localized management and operations.
• Start localized registration of IVD products in Europe in 2026.
• Continue efforts to raise additional capital through debt from related parties/stockholders and equity financing.
• Work towards obtaining required registration certificates for products by October 2027.

Key Dates

Recommendation

The filing presents a highly concerning financial picture for Advanced Biomed Inc. The significant increase in net loss and cash used in operating activities, coupled with an explicit 'substantial doubt about the ability to continue as a going concern' warning, indicates severe financial distress. While the company has secured an ELOC agreement and completed an IPO, these are insufficient to offset the current burn rate and the stated expectation of continuous losses for the next two to three years. The reliance on future capital raises, which are uncertain in terms of availability and terms, further exacerbates the risk. For a seasoned investor, the fundamental financial instability and the explicit going concern risk outweigh any potential long-term product development upside, making it a strong sell recommendation.

Keywords

Advanced Biomed Inc, ADVB, 10-Q, Quarterly Report, Biotechnology, Oncology, Cancer Detection, Microfluidic Biochip, Clinical Trials, Regulatory Approval, NMPA, Going Concern, Net Loss, Cash Flow, R&D Expenses, Capital Raise, ELOC Agreement, Taiwan, China, Nasdaq